Open AccessDraft Genome Sequence of Proteus mirabilis NO-051/03, Representative of a Multidrug-Resistant Clone Spreading in Europe and Expressing the CMY-16 AmpC-Type β-Lactamase
Author(s) -
Marco Maria D’Andrea,
Tommaso Giani,
Lucia Henrici De Angelis,
Nagaia Ciacci,
Marek Gniadkowski,
Vivì Miriagou,
Francesca Torricelli,
Gian María Rossolini
Publication year - 2016
Publication title -
genome announcements
Language(s) - English
Resource type - Journals
ISSN - 2169-8287
DOI - 10.1128/genomea.01702-15
Subject(s) - proteus mirabilis , biology , replicon , plasmid , genome , multiple drug resistance , whole genome sequencing , crispr , clone (java method) , genetics , microbiology and biotechnology , computational biology , gene , drug resistance , escherichia coli
Proteus mirabilis NO-051/03, representative of a multidrug-resistant clone expressing the CMY-16 AmpC-type β-lactamase and circulating in Europe since 2003, was sequenced by a MiSeq platform using a paired-end approach. The genome was assembled in 100 scaffolds with a total length of 4,197,318 bp. Analysis of the draft genome sequence revealed the presence of several acquired resistance determinants to β-lactams, aminoglycosides, phenicols, tetracyclines, trimethoprim, and sulfonamides, of one plasmid replicon, and of a type I-E clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein (Cas) adaptive immune system.